Short-term clinical outcomes among treatment-experienced HIV-positive patients with early low level viremia

AIDS Patient Care and STDs

Volumn 26, Issue 5, 2012, Pages 253-255

  Chao, Chun ^a   Tang, Beth ^a   Towner, William ^b   Silverberg, Michael J ^c   Hurley, Leo ^c   Horberg, Michael ^a  

^a KAISER PERMANENTE   (United States)

^b LOS ANGELES MEDICAL CENTER   (United States)

^c DIVISION OF RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CD4 LYMPHOCYTE COUNT; DEATH; DISEASE REGISTRY; ELECTRONIC MEDICAL RECORD; FOLLOW UP; HEALTH CARE PLANNING; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; LOW LEVEL VIREMIA; MALE HOMOSEXUAL; OUTCOME ASSESSMENT; SOCIOECONOMICS; TREATMENT FAILURE; VIREMIA;

ANTI-HIV AGENTS; FEMALE; HIV SEROPOSITIVITY; HUMANS; MALE; MIDDLE AGED; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD; VIREMIA;

EID: 84860433489     PISSN: 10872914     EISSN: 15577449     Source Type: Journal    
DOI: 10.1089/apc.2012.0035     Document Type: Letter

References (8)

1. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000;133:21-30 (Pubitemid 30432540)
2. Guidelines for the Use of AntiretroviralAgents in HIV-1- Infected Adults and Adolescents. pp. 1-166. www.aidsinfo .nih.gov/ContentFiles/ AdultandAdolescentGL.pdf (Last accessed August 31, 2011)
3. Cohen C. Low-level viremia in HIV-1 infection: Consequences and implications for switching to a new regimen. HIV Clin Trials 2009;10:116-124
4. Raffanti SP, Fusco JS, Sherrill BH, et al. Effect of persistent moderate viremia on disease progression during HIV therapy. J Acquir Immune Defic Syndr 2004;37:1147-1154 (Pubitemid 39166649)
5. Murri R, Lepri AC, Cicconi P, et al. Is moderate HIV viremia associated with a higher risk of clinical progression in HIVinfected people treated with highly active antiretroviral therapy: Evidence from the Italian cohort of antiretroviralnaive patients study. J Acquir Immune Defic Syndr 2006;41: 23-30 (Pubitemid 41786015)
6. Tarwater PM, Gallant JE, Mellors JW, et al. Prognostic value of plasma HIV RNA among highly active antiretroviral therapy users. AIDS 2004;18:2419-2423 (Pubitemid 40065909)
7. Brigido L, Rodrigues R, Casseb J, et al. CD4+ T-cell recovery and clinical outcome in HIV-1-infected patients exposed to multiple antiretroviral regimens: Partial control of viremia is associated with favorable outcome. AIDS Patient Care STDs 2004;18:189-198 (Pubitemid 38552651)
8. Tenorio AR, Jiang H, Zheng Y, et al. Delaying a treatment switch in antiretroviral-treated HIV type 1-infected patients with detectable drug-resistant viremia does not have a profound effect on immune parameters: AIDS Clinical Trials Group Study A5115. AIDS Res Hum Retroviruses 2009;25: 135-139